Nebenwirkungen · NovoRapid
NovoRapid 100 units/ml solution for injection in vial NovoRapid Penfill 100 units/ml solution for injection in cartridge NovoRapid FlexPen 100 units/ml solution for injection in pre-filled pen NovoRapid InnoLet 100 units/ml solution for injection in pre-filled pen NovoRapid FlexTouch 100 units/ml solution for injection in pre-filled pen NovoRapid PumpCart 100 units/ml solution for injection in cartridge · Abschnitt 4.8 · PDF-Seite 8
HOS-090215 · Präparat HOS-084033
At the beginning of the insulin treatment, refraction anomalies, oedema and injection site reactions (pain, redness, hives, inflammation, bruising, swelling and itching at the injection site) may occur. These reactions are usually of transitory nature. Fast improvement in blood glucose control may be associated with acute painful neuropathy, which is usually reversible. Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-28T02:00:00Z · SHA-256 596b72a285a1a6a53ef22a3d8e8f5b78afcad8d6266d30dcb5e7e2429eede7f2 · Passage c1dd600f72aa0ebfc09c0277c89eee1fc6c06eb70a379c5771c0465d54b5e459 · Zeichen 394–1016 im Abschnitt